Merck Teams With Lycera In Second Autoimmune Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Michigan-based biotech says the latest discovery and development deal with Merck is validation of its ongoing work with the Big Pharma in the field of autoimmune diseases.